ArticleClinical lymphoma, myeloma & leukemia2019
Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab Treatment.
Article in Clinical lymphoma, myeloma & leukemia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Cytomegalovirus Retinitis Following Daratumumab for Multiple Myeloma: A Case Report and Literature Review.Case reports in medicine · 2025Article
- Cytomegalovirus infection during daratumumab therapy in patients with newly diagnosed multiple myeloma.International journal of hematology · 2024Article
- Cytomegalovirus reactivation is frequent in multiple myeloma patients treated with daratumumab-based regimens.Cancer medicine · 2024Article
- Toxicity management strategies for next-generation novel therapeutics in multiple myeloma.Therapeutic advances in hematology · 2022Review
- Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network.Leukemia · 2021Review
- EBV-related lymphoma after long-term daratumumab treatment: a case report.Blood cancer journal · 2020Article
- Hepatitis B virus reactivation in a myeloma patient with resolved infection who received daratumumab-containing salvage chemotherapy.Journal of clinical and experimental hematopathology : JCEH · 2020Article
- Daratumumab is a safe and effective rescue therapy for multiple myeloma patients who relapse after allo-HSCT.Bone marrow transplantation · 2020Article
- Do cytomegalovirus infections affect the daratumumab treatment course in multiple myeloma patients? - Literature review.Hematology, transfusion and cell therapyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.